Findings from a Czech registry study suggest that pirfenidone treatment is associated with a lasting reduction in lung function decline and mortality risk among patients with idiopathic pulmonary fibrosis.
Findings from a large US study suggest that early treatment with antibiotics is not associated with improved outcomes among patients hospitalised for asthma exacerbation and treated with systemic corticosteroids.
A number of exhaled biomarkers have the potential to discriminate between patients with idiopathic pulmonary fibrosis and healthy controls, but further work is needed to confirm their clinical utility, say the authors of a systematic review.
Patients with asthma who are treated with the once-daily inhaled corticosteroid/long-acting beta agonist regimen fluticasone furoate/vilanterol have better treatment adherence than those taking the twice-daily budesonide/formoterol combination, researchers report.
A genome-wide association study has identified novel genetic variants associated with the risk of developing moderate-to-severe asthma, a substantial proportion of which are also associated with mild asthma susceptibility.
Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.
Patients with idiopathic pulmonary fibrosis who have previously experienced disease progression whilst receiving pirfenidone may benefit from continued treatment with the antifibrotic agent, researchers report.
Preliminary findings from the phase II PRESIS trial suggest that preventative treatment with inhaled hypertonic saline is well tolerated and may improve lung clearance index in young infants with cystic fibrosis.
An intervention combining transitional care and self-management support after hospital discharge reduces the number of subsequent hospital visits and improves health-related quality of life among patients with chronic obstructive pulmonary disease, trial findings indicate.
The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.
Combination therapy with a next-generation cystic fibrosis transmembrane conductance regulator corrector, together with tezacaftor and ivacaftor, may be a promising treatment option for cystic fibrosis, suggest findings from two studies published in The New England Journal of Medicine.
The addition of low-dose theophylline to inhaled corticosteroids does not reduce the risk of exacerbations among patients with chronic obstructive pulmonary disease, findings from the TWICS trial indicate.
In 5-year-old children with cystic fibrosis, positivity for Aspergillus species in bronchoalveolar lavage cultures is associated with air trapping but not with bronchiectasis or reduced lung function, indicates a longitudinal study.